Highest-materiality recent filing
Chiesi completes $27/share acquisition of KalVista; shares cease trading on Nasdaq
Tender offer accepted 43,152,532 shares (~77.8% of outstanding) at $27.00 cash per share.
Chiesi Group to acquire KalVista Pharmaceuticals for $27.00 per share, ~$1.9bn
Chiesi will acquire all KalVista shares for $27.00/sh cash, a 36% premium to 30-day VWAP as of April 28, 2026.
KalVista reports $49.1M EKTERLY revenue in 8mo transition period, 1,702 patient start forms
Global net product revenue of $49.1M from EKTERLY (sebetralstat) for May–Dec 2025; first commercial sales since launch on July 7, 2025.
KalVista reports preliminary Q4 EKTERLY revenue of ~$35M, full-year ~$49M; 1,318 patient start forms
Preliminary unaudited global net product revenue: ~$35M for Q4 2025, ~$49M for full year 2025.
Net product revenue of $13.7M for Q3 ended Sept 30, 2025, first full quarter of EKTERLY commercial launch.
KalVista closes $143.75M convertible notes offering; net proceeds ~$139M for EKTERLY
Issued $143.75M in 3.250% Convertible Senior Notes due 2031, including full exercise of $18.75M greenshoe.
KalVista Q1: EKTERLY approved in US/UK; 460 patient start forms; positive CHMP opinion
EKTERLY (sebetralstat) FDA approved July 7, 2025; UK MHRA authorized same month; positive CHMP opinion; EU decision expected Oct 2025.
KalVista FY2025: FDA approved EKTERLY; cash $220.6M; R&D down, G&A up
FDA approved EKTERLY (sebetralstat) on July 7, 2025 as first oral on-demand HAE treatment; U.S. launch underway.
KalVista receives FDA approval for EKTERLY (sebetralstat), first oral on-demand HAE treatment
FDA approved EKTERLY for acute attacks of hereditary angioedema in patients 12+ years; first oral on-demand therapy.
KalVista COO Jebediah T. Ledell resigns effective May 12, 2025
COO Jebediah T. Ledell resigned effective immediately on May 12, 2025.
KalVista licenses sebetralstat Japan rights to Kaken; $11M upfront, up to $24M total plus royalties
Upfront payment of $11M plus up to $11M regulatory milestone expected in early 2026.
KalVista Q3 fiscal 2025: $253.2M cash, sebetralstat regulatory progress; PDUFA June 17
No revenue; R&D expense $12.6M (down from $22.5M YoY); G&A $30.3M (up from $10.6M) due to pre-commercial activities.
KalVista appoints Jeb Ledell as COO; base salary $500k, 100k stock options
Jebediah T. Ledell appointed COO effective December 16, 2024; brings 20+ years biotech ops experience.
KalVista Q2 FY2025: No revenue, cash $135.8M; sebetralstat NDA accepted with PDUFA June 17, 2025
R&D expenses $16.6M, G&A $29.2M; pro forma cash $292.2M after $156.4M net November raise.
KalVista secures up to $179M synthetic royalty financing with DRI for sebetralstat launch
Upfront payment of $100M; potential total up to $179M including $22M optional approval payment and $57M sales milestone.
KalVista raises $60M in public offering and private placement to fund sebetralstat
Public offering of 5.5M shares at $10.00 per share for gross proceeds of $55M; net ~$51.3M.
KalVista Q1 net loss $40.4M; FDA accepts NDA for sebetralstat, PDUFA June 17, 2025
Net loss $40.4M ($0.87/share) vs $25.3M prior year; no revenue recognized.
KalVista submits NDA for sebetralstat; FY2024 net loss $126.6M
NDA submitted to FDA for sebetralstat, first oral on-demand HAE treatment; potential approval H1 2025.
KalVista reports Phase 3 KONFIDENT success for sebetralstat, CEO transition, $150M financing
Phase 3 KONFIDENT met all primary and key secondary endpoints; sebetralstat safety profile similar to placebo.
KalVista appoints Benjamin Palleiko as CEO; Crockett resigns in planned transition
T. Andrew Crockett resigned as CEO and board director effective March 6, 2024, not due to any disagreement.
KalVista prices $160.1M public offering of common stock and pre-funded warrants
Offering includes 7,016,312 shares at $15.25 and pre-funded warrants for 3,483,688 shares; gross proceeds $160.1M.
Sebetralstat 300 mg achieved beginning of symptom relief in median 1.61 hours vs placebo 6.72 hours (p<0.0001).
KalVista hits Phase 3 attack target for sebetralstat; NDA on track for H1 2024
Phase 3 KONFIDENT trial achieved targeted number of attacks; data readout early 2024, NDA filing expected H1 2024.
KalVista reports Q1 FY2024 net loss $25.3M; KONFIDENT phase 3 enrollment achieved
Net loss $25.3M ($0.74/share) vs $23.0M ($0.94/share) in prior-year quarter.
KalVista FY2023 net loss $92.9M; sebetralstat Phase 3 enrollment complete
Phase 3 KONFIDENT trial achieved target enrollment (114 patients); data readout expected Q4 2023; NDA planned H1 2024.
KalVista reports Q3 net loss $21.3M; sebetralstat phase 3 enrollment >50%, data H2 2023
Net loss $21.3M ($0.75 per share), no revenue; R&D $20.1M, G&A $6.9M.
KalVista promotes CFO/CBO Palleiko to President; cites $190M cash for sebetralstat launch prep
Benjamin L. Palleiko appointed President effective Jan 4, 2023, while retaining CFO and CBO roles.
KalVista raises ~$58M in registered direct offering of 9.48M shares at $6.00/share plus warrants
9,484,199 shares at $6.00 per share, plus pre-funded warrants for 182,470 shares at $5.999 each.
KalVista terminates KVD824 Phase 2 trial over liver enzyme elevations; net loss widens to $22.3M
Phase 2 KOMPLETE trial for KVD824 terminated due to patient liver enzyme elevations; future development uncertain.
Martin Edwards resigned as Chairman and director effective immediately; departure not due to any disagreement.
KalVista Q1 net loss $23.0M ($0.94/share); cash $142.1M, down $24.1M from April
No revenue; R&D spending rose to $18.2M (vs. $13.7M a year ago), driven by Phase 3 KONFIDENT and preclinical costs.
KalVista reports Q3 net loss $22.5M; KVD900 Phase 3 trial initiated, data expected H2 2023
Net loss of $22.5M ($0.92/share) vs $10.0M loss ($0.56) YoY; R&D spend $19.7M (up from $9.1M).
KalVista initiates Phase 3 KONFIDENT trial of KVD900 for HAE attacks
KVD900 is first potential oral on-demand therapy for HAE; all current on-demand therapies are injectable.
KalVista reports Q2 net loss $19.7M; advances HAE oral candidates KVD900 and KVD824
Net loss of $19.7M ($0.80 per share) for quarter ended Oct 31, 2021 vs $10.4M ($0.58) year ago.
FDA lifts clinical hold on KalVista's Phase 2 KVD824 trial for HAE prophylaxis
FDA removed clinical hold on Phase 2 KOMPLETE trial of KVD824 for oral prophylactic treatment of hereditary angioedema.
each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors
each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors
each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors
John Hess, the sole director of Purchaser immediately prior to the Effective Time, became the sole director of the Company
each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors
each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors
each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors
each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors
each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors
John Hess, President and Secretary of Purchaser, became an officer of the Company.
On May 12, 2025, Jebediah T. Ledell notified KalVista Pharmaceuticals, Inc. (the “Company”) of his decision to resign from his position as Chief Operating Officer of the Company, effective immediately.
Effective September 9, 2024, the Board of Directors (the “Board”) of KalVista Pharmaceuticals, Inc. (the “Company”) appointed Brian Piekos as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer.
Max materiality 1.00 · Median 0.65 · Most common event earnings